These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011 [TBL] [Abstract][Full Text] [Related]
26. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271 [TBL] [Abstract][Full Text] [Related]
27. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952 [TBL] [Abstract][Full Text] [Related]
28. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357 [TBL] [Abstract][Full Text] [Related]
29. NSCLC and HER2: between lights and shadows. Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338 [TBL] [Abstract][Full Text] [Related]
30. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964 [TBL] [Abstract][Full Text] [Related]
31. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
32. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409 [TBL] [Abstract][Full Text] [Related]
33. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib. Liu R; Ota K; Iwama E; Yoneshima Y; Tanaka K; Inoue H; Tagawa T; Oda Y; Mori M; Nakanishi Y; Okamoto I Lung Cancer; 2021 Aug; 158():156-161. PubMed ID: 34059353 [TBL] [Abstract][Full Text] [Related]
35. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
36. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation]. Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549 [No Abstract] [Full Text] [Related]
37. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558 [TBL] [Abstract][Full Text] [Related]
38. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. Liu L; Shao X; Gao W; Bai J; Wang R; Huang P; Yin Y; Liu P; Shu Y J Thorac Oncol; 2010 Dec; 5(12):1922-32. PubMed ID: 21155183 [TBL] [Abstract][Full Text] [Related]
39. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500 [TBL] [Abstract][Full Text] [Related]
40. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]